Catalent buys partially built biologics plant with plans to shell out $160M to finish it

CDMO giant Catalent has snapped up a biologics development and manufacturing facility in the U.K. and will shell out $160 million to wrap up construction there.

The facility is located near Oxford at the Harwell Science and Innovation Campus that serves as home to more than 40 life sciences companies. Catalent bought it from the Vaccine Manufacturing and Innovation Centre.